TABLE 2.
Numbers and proportions of cases and controls exposed and estimated ORs, controlling for matching variables, with confidence intervals
| Exposure | Cases N = 25,216 | Controls N = 126,080 | OR (95% CI) |
|---|---|---|---|
| Neurofibromatosis type II | 117 (0.5) | 30 (0.02) | 19.5 (13.1–29.1) |
| Exposure to at least one of the progestogens | |||
| Current use | 2497 (9.9) | 2382 (1.9) | 6.7 (6.3–7.1) |
| Short‐term use <1 year | 206 (0.8) | 861 (0.7) | 1.2 (1.0–1.4) |
| Prolonged use ≥1 year | 2291 (9.1) | 1521 (1.2) | 9.5 (8.8–10.2) |
| Cyproterone acetate | |||
| Current use | 961 (3.8) | 290 (0.2) | 18.3 (16.0–21.1) |
| Short‐term use <1 year | 30 (0.1) | 63 (0.05) | 2.4 (1.5–3.7) |
| Prolonged use ≥1 year | 931 (3.7) | 227 (0.2) | 22.7 (19.5–26.4) |
| Nomegestrol acetate | |||
| Current use | 969 (3.8) | 1149 (0.9) | 4.7 (4.3–5.1) |
| Short‐term use <1 year | 105 (0.4) | 421 (0.3) | 1.3 (1.0–1.6) |
| Prolonged use ≥1 year | 864 (3.4) | 728 (0.6) | 6.5 (5.8–7.2) |
| Chlormadinone acetate | |||
| Current use | 683 (2.7) | 1096 (0.9) | 3.3 (3.0–3.6) |
| Short‐term use <1 year | 80 (0.3) | 416 (0.3) | 0.9 (0.8–1.2) |
| Prolonged use ≥1 year | 603 (2.4) | 680 (0.5) | 4.7 (4.5–5.3) |
Note: Current use: exposed at least once within 365 days before the index date, regardless of former exposure. Short‐term use: exposed within 365 days before the index date, excluding the period between 365 and 730 days before the index date. Prolonged use: exposed both within 365 days and between 365 and 730 days before the index date.
Abbreviations: CI, confidence interval; OR, odds ratio, controlling for matching factors (sex at birth, year of birth and area of residence).